Similar articles

• Fundamentals of active specific immunotherapy of cancer using BCG-tumor cell vaccines.

  Hanna MG Jr, Peters LC, Hoover HC Jr. Hanna MG Jr, et al. Prog Clin Biol Res. 1989;310:51-65. Prog Clin Biol Res. 1989. PMID: 2672023 Review. No abstract available.
• Overview of tumor cell-based vaccines.

  Copier J, Dalgleish A. Copier J, et al. Int Rev Immunol. 2006 Sep-Dec;25(5-6):297-319. doi: 10.1080/08830180600992472. Int Rev Immunol. 2006. PMID: 17169778 Review.
• [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].

  Prikler L, Scandella E, Men Y, Engeler DS, Diener PA, Gillessen S, Ludewig B, Schmid HP. Prikler L, et al. Aktuelle Urol. 2004 Aug;35(4):326-30. doi: 10.1055/s-2004-818510. Aktuelle Urol. 2004. PMID: 15459874 German.
• Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells.

  Schirrmacher V, von Hoegen P, Heicappell R. Schirrmacher V, et al. Prog Clin Biol Res. 1989;288:391-9. Prog Clin Biol Res. 1989. PMID: 2785693 No abstract available.
• Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.

  Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM. Toes RE, et al. Behring Inst Mitt. 1994 Jul;(94):72-86. Behring Inst Mitt. 1994. PMID: 7998917 Review.